Objective:

To assess the LDL-C-lowering effectiveness and safety profile of LivaloZet® Tablets in Korean patients with dyslipidemia and metabolic syndrome.

Approach:

• Study Design: Multi-center, non-interventional, prospective observational study enrolling up to 10,000 Korean adult patients.
• Participants: Korean adults with dyslipidemia and metabolic syndrome prescribed LivaloZet® Tablets.
• Endpoints: Primary endpoint: percent change in LDL-C at Week 24. Secondary endpoints: LDL-C changes at Week 48, full lipid panel changes, and LDL-C target achievement rates.
• Safety Assessments: Monitored through adverse events, laboratory tests, and vital signs, including liver and muscle function tests.

Key Findings:

• Dyslipidemia and metabolic syndrome significantly increase cardiovascular risk.
• LivaloZet® combines pitavastatin and ezetimibe for effective LDL-C reduction.
• The study will provide real-world evidence on the effectiveness and safety of LivaloZet®.

Interpretation:

The study aims to generate descriptive data on the effectiveness and safety of LivaloZet® in a real-world setting, focusing on LDL-C reduction and metabolic safety.

Limitations:

• Non-randomized, single-arm observational design limits causal inference.
• Potential confounding by indication and selection bias.
• Inter-laboratory variability may affect results.

Conclusion:

The PIVOT study will offer insights into the LDL-C-lowering effectiveness and safety of LivaloZet® in patients with dyslipidemia and metabolic syndrome.

Sources:

• ClinicalTrials.gov